Search This Blog

Thursday, August 9, 2018

Surgery centers don’t have to report deaths in 17 states


The first man died in April 2014. Another died later that month. Then, on July 18 of that year, a woman was rushed to a hospital where she was told she was lucky to be alive.
They all went to the same Little Rock, Arkansas, surgery center for a colonoscopy, among the safest procedures a patient can have. And each stopped breathing soon afterward, court records say, sustaining the same type of brain damage seen in a drowning victim.
What happened at Kanis Endoscopy Center prompted no review by officials in Arkansas, which, like 16 other states, has no mandate to report patient deaths after surgery center care. So no facility oversight authority has examined whether the deaths were a statistical anomaly or cause for alarm.
A USA TODAY NETWORK and Kaiser Health News investigation found that surgery centers operate under such an uneven mix of rules across U.S. states that fatalities or serious injuries can result in no warning to government officials, much less to potential patients. The gaps in oversight enable centers hit with federal regulators’ toughest sanctions to keep operating, according to interviews, a review of hundreds of pages of court filings and government records obtained under open records laws. No rule stops a doctor exiled by a hospital for misconduct from opening a surgery center down the street.
Even the high-profile death of comedian Joan Rivers – who passed away in 2014 following a routine procedure at a Manhattan surgery center – failed to appear in Medicare’s public tally of patients rushed to a hospital.
When Faye Watkins, 63, walked into Kanis Endoscopy in Arkansas, she said she was unaware there had been two deaths after care there within the previous three months. She was in the fog of anesthesia when it struck her that something was amiss. She said she heard men say her blood pressure was falling.
“I said (to myself), ‘Lord, if it’s time for me to go, take me. But I’m not ready,’ ” Watkins recalled. Her next memory was waking up in a hospital with her chest sore from CPR.
The KHN/USA TODAY examination raises questions about the need for more robust oversight of surgery centers, where public access to important information, such as surgical outcome data, tends to be more limited than what’s available about hospitals. The gap persists even as the nation’s 5,600 surgery centers have surpassed hospitals in number and taken on increasingly complex procedures.
“It’s disgraceful that there’s so little information” about what happens in surgery centers, said Leah Binder, chief executive of the Leapfrog Group, an employer consortium that surveys more than 2,000 hospitals a year.
Scrutinizing unexpected deaths is the norm for U.S. hospitals. The Joint Commission, their leading accreditation body, recommends members send the accreditor reports of unexpected deaths so that lessons from one tragedy might prevent another. The top surgery center accreditation body has no similar guideline.
Bill Prentice, executive director of the Ambulatory Surgery Center Association, an organization that represents the centers in policymaking discussions, said the centers safely perform millions of procedures, from tonsillectomies to knee replacements, each year.
Prentice said he supports giving patients access to data that could compare surgery centers with hospital outpatient departments.
“We shouldn’t have a patchwork system where one state asks for one thing and others ask for others,” Prentice said. “What consumers want is consistency.”
Colorado requires surgery centers to report deaths and some major injuries to the state health department, and the agency posts summaries of incidents online for consumers. Several other states – including Pennsylvania, Florida and New Jersey – require incident reports but don’t reveal to the public where they happened.
In at least 17 states, health facility officials confirmed they have no way to know that a patient died because surgery centers have no duty to report. So just as in Arkansas, surgery centers had no mandate to notify an official over cases outlined in lawsuits, including a 33-year-old Missouri man who died after finger surgery, a 66-year-old Georgia woman who died after an eye procedure or a 60-year-old in Oklahoma who died soon after a total hip replacement.
Even in Colorado, a leader in transparency, the outcome of a 2017 jury trial raised questions about the depth of the oversight. Robbin Smith was paralyzed from the waist down after an epidural pain injection at the Surgery Center at Lone Tree in 2013, according to her lawsuit against the center.
Smith’s attorneys cited Medicare rules that say the center’s own governing body has a duty to keep patients safe. Each center must appoint a body that is legally responsible for the center’s operations.
Smith’s legal team argued that the center should have upheld its duty by ensuring that its doctors did not use the drug Kenalog – an injectable steroid – for epidural injections. The drugmaker had changed the label in 2011 to warn against using it that way due to the risk of paralysis.
The center’s governing body never discussed proper usage of the drug prior to Smith’s care, trial testimony shows, and there’s no sign that state or private facility overseers examined the board’s actions before Smith’s injury.
The surgery center’s lawyer argued that the doctor – not the facility – was responsible for choosing Kenalog for Smith’s treatment. The doctor denied wrongdoing and reached a confidential settlement with Smith before her case against the center went to trial.
Jurors ultimately ruled against the center, awarding Smith $14.9 million. The center has filed a motion for a new trial.

Public reports flawed

The federal government posts on its “Hospital Compare” website far more data about hospitals than surgery centers, and available hospital data cover several types of surgical complications and mortality rates for certain conditions. Some hospitals’ quality measures, such as infection rates or patient satisfaction scores, reflect the experience of every patient in the hospital.
The same Medicare website displays different data for surgery centers – and for some key measures, the reported results cover only a fraction of patients. Medicare allows surgery centers to report data for as few as half of just their Medicare patients, ignoring most patients under age 65 who do not yet qualify for Medicare.
In practice, that has allowed surgery centers to report as many hospital transfers as they choose – unless more than half of their patients leave by ambulance.
Yet a person examining the data on the Medicare website would see no explanation about the limits of the information. They would see a national transfer rate that’s less than half the rate reported in medical research.
State records, ambulance records and Medicare’s own inspection reports highlight the apparent disconnect. They show that dozens of centers reporting zero transfers in Medicare’s public data do, in fact, send patients to hospitals.
For example, Memphis, Tennessee-based Urocenter, which specializes in urological procedures, reported to state officials 45 transfers combined in 2014 and 2015. Its public report on the Medicare website for those years showed zero transfers.
When a reporter noted the discrepancy, Urocenter’s administrator responded in an email that the facility “put in place corrective measures … and have provided (Medicare) with the corrected information.”
The Medicare data also show zero transfers in 2014 from Yorkville Endoscopy. The Manhattan surgery center transferred Joan Rivers, 81, to a hospital after complications from a vocal cords procedure that year. Rivers died a week later.
An attorney for Yorkville Endoscopy said all transfers meeting the government’s standards were reported.
After reviewing the reporting rules, Cheryl Damberg, a RAND Corp. researcher who has worked on hospital quality-reporting tools for the federal government, said the 50 percent rule leaves the public with little useful information.
“It seems like this can totally be gamed,” Damberg said. “From a consumer standing, the data (for surgery centers) doesn’t have a lot of utility at this point.”
Medicare officials said in an interview that the agency allows limited reporting so the requirements do not overburden surgery centers.
Yet industry leaders have told Medicare they want to report more data. In letters to Medicare during 2016 and 2017 rule-making periods, the ASC Quality Collaboration, a group of surgery center leaders, urged Medicare to collect reports on every patient transfer to expand transparency and accountability.
Medicare made a very different move in July, proposing to stop collecting surgery center-to-hospital transfer data and seven other measures of quality. The agency said it still plans to report on incidents gleaned from its own records, such as visits to the hospital seven days after certain surgery center procedures.
Medicare said in the proposed rule that the transfer measure appears to be “topped out,” meaning there is a tiny difference in transfer rates reported by the centers.
Dr. Ashish Jha, a senior associate dean at Harvard’s School of Public Health, said calling the data “topped out” is puzzling since Medicare is not sampling all of the patients.
“Getting rid of (the transfer measure) doesn’t make a lot of sense to me,” he said.
Prentice, of the surgery center association, lauded the proposal in a press release as recognizing the “outstanding” work of surgery centers in preventing harm. In an interview, he conceded that he was “parroting” Medicare’s sentiment and said he hopes the industry will find a way to report meaningful quality data.

Cluster of cases

Medicare’s rules for surgery centers require them to track unusual events, analyze them internally and try to learn from them. But after two deaths and a close call following procedures at Kanis Endoscopy Center, no outside official went in to see if patients remained at risk.
Medicare spokesman Tony Salters confirmed that lacking a consumer complaint, no state or federal official was notified of the events and no special review occurred.
Yet what happened in a stretch of three months was far from routine. In April 2014, Rev. Ronald Smith, 63, died at a hospital after visiting Kanis for a colonoscopy. His family later alleged in a lawsuit that Smith’s sleep apnea and heart disease made him “extremely high risk” for undergoing anesthesia at the center, rather than at a hospital.
Smith was close to death at the Little Rock hospital when, coincidentally, an Arkansas health official began a routine inspection of the center on behalf of Medicare, records show. The lack of public information makes it impossible to determine precisely what happened in Smith’s case.
Medicare spokesman Bob Moos said state recertification inspectors come in every four to seven years and review all cases in the previous year in which a surgery center patient was transferred to a hospital. When the state inspector visited Kanis, “nothing on the hospital transfer log raised a red flag for her to investigate,” the spokesman said.
Officials would not describe what was on the transfer log or which cases were on it or confirm that Smith’s name had been included on it.
A Kanis spokesperson said it would violate patient confidentiality to comment on what the staff showed the inspector. Arkansas Department of Health spokeswoman Meg Mirivel provided no details, saying state law prohibits releasing information about hospital or surgery center investigations.
The state official’s inspection report does not mention any patient transfers. It does say the center was operating outside of industry norms by performing colonoscopies without an additional nurse in the room. The center pledged to health officials that it would add a nurse to the endoscopy suites.
The extra set of hands can be critical in case of an airway failure, said Dr. John Dombrowski, an anesthesiologist and a board officer with the American Society of Anesthesiologists.
“When you have an airway problem, you’ve got minutes,” he said. “When you have more hands on deck, you’re better able to save somebody.”
About three hours after the inspector left Kanis, another ambulance was speeding to the center.
It remains unclear if another medical professional would have helped save Clarence Creggett, 83, who also stopped breathing at the center after his colonoscopy, according to his family’s lawsuit. He died in a hospital nine days later, the family alleged.
Creggett’s family also filed a lawsuit, alleging that he was at “extremely high risk” as a surgery center patient, given his age and history of respiratory problems, including asthma.
Watkins, who survived after she stopped breathing, according to her lawsuit, said she only learned about the deaths of Smith and Creggett through gossip at her bank and hair salon. “My eyes got big then,” Watkins said. “That’s how I actually found out.”
Attorney Lamar Porter filed lawsuits in Pulaski County, Arkansas, on behalf of Watkins and the families of Smith and Creggett. The suit alleged that Dr. Alonzo Williams, who performed all three procedures, failed to properly screen the patients. The suits also claim that the nurse anesthetists did not administer the anesthesia appropriately.
The endoscopy center denied wrongdoing in court filings, and the suits ultimately ended with confidential settlements. Suzette Siegler, director of Kanis, stated in a letter that the center “strives to provide the very best care possible.”
The anesthetists also denied fault or negligence in legal filings. Dustin Wixson, the nurse anesthetist on the Creggett case, said the death was the only one in his 14-year career.
Williams denied wrongdoing in court filings for each case. He did not respond to requests for comment. Siegler’s letter stated that he was dismissed from the lawsuits before they settled and has “practiced for over 35 years with an unassailable reputation nationally. He was appointed by three separate Arkansas Governors to (the) Arkansas State Medical Board.”

Crackdowns that don’t stick

Medicare inspectors have a harsh sanction they mete out sparingly after serious safety lapses: involuntary decertification. It means the federal government won’t pay for seniors’ care at a health facility.
Such actions cut off a major source of patients and payments to hospitals and tend to make headlines. Hospitals that were involuntarily decertified in recent years closed for good, had to reopen as a clinic or reorganized before seeing another patient.
But surgery centers hit by such penalties have hardly skipped a beat.
Medicare pulled its certification from Cascade Cosmetic Surgery Center in Orem, Utah, on Dec. 28, 2014, after state inspectors said the center failed to meet basic standards mandated by federal regulations.
Medicare requires a surgery center to have a governing body that has formal meetings and takes legal responsibility for providing “quality health care in a safe environment.” According to the inspection report, the Utah center’s owner, Dr. Trenton Jones, told the inspector “he was the governing body and that he did not keep minutes of his thoughts.”
The inspection also said the center did not meet Medicare’s infection-control rules, such as putting a licensed professional in charge, determining what kind of bacteria infected patients or logging antibiotic use.
In some states, licensing officials would follow Medicare’s lead and revoke their approval. But in Utah, any licensed surgeon can operate in a one-operating-room surgery center without state approval, said Tom Hudachko, spokesman for the Utah Department of Health.
That meant Cascade was open for business – five days after Medicare pulled its approval – when Sandy Lee Walters, a 37-year-old real estate agent and mother of three, flew to Utah from Hawaii for breast reduction, tummy tuck and liposuction surgeries. The procedures took nearly nine hours, from 2:30 p.m. to 11:20 p.m., court records show.
Five days later, Walters died after a blood clot lodged in her lung. Her autopsy report notes “recent surgery” as a “significant contributing condition” in her death.
A lawsuit filed by her family alleged that Walters was at high risk for a blood clot because of her recent air travel and the extent of the surgery, yet she was not prescribed a “sequential” compression device or clot-busting medication. The suit is ongoing.
Walters’ eldest daughter testified in a deposition that her brother treasures a blanket his grandmother made from his mother’s blue jeans. “We all have a little piece of us missing,” the teen testified.
Three months after Walters’ death, a 55-year-old woman went to the same surgery center to have her breast implants removed. Within a week, the woman was found to have infections so severe that her nipples had to be removed in subsequent surgeries. In 2017, the woman filed a lawsuit alleging malpractice by Jones and the center. The suit is ongoing.
Cascade, Jones and his attorneys did not return calls or emails seeking comment. In both lawsuits, Cascade and Jones denied the allegations, according to court documents.
In California, eight centers that Medicare decertified over health violations have continued to operate on patients, with the blessing of private accreditation agencies hired by the centers to perform inspections. They include a center that was operating without a lifesaving drug in the crash cart and a facility where managers pressed an unqualified receptionist into duty disinfecting scopes used inside the body.
A Medicare official said accreditation bodies are notified when the agency pulls an approval, but officials do not control the private body’s decisions.

Owners in charge

Hospitals have committees and administrators focused on making sure doctors’ skills are sharp and their insurance is in place. Surgery centers have similar rules, but the oversight is lacking when a controversial doctor is also the facility owner.
Dr. Paul Mackoul, a Maryland gynecological surgeon, lost his hospital privileges in 2001 after a medical staff committee at Washington Hospital Center reviewed his “competence or conduct,” according to Washington, D.C., Board of Medicine records. Mackoul criticized the decision, saying he never had a chance to defend himself.
Mackoul has faced 14 lawsuits since 1991 alleging substandard obstetrics and gynecological care, according to court records. Women have accused him of leaving them infertile, incontinent or with perforated bowels. Mackoul said in an email that settlements were paid on his behalf in four cases, two were decided in his favor at trial, one case is pending and the others were dismissed or resulted in no payment on his behalf.
Despite losing privileges at Washington Hospital Center, Mackoul and his wife, who is also a gynecologist, co-own and operate Innovations Surgery Center in Rockville, Maryland. The facility is Medicare-approved, based on the recommendation of an accreditation body.
An insurer’s lawsuit shows that in early 2015, Mackoul’s malpractice policy did not cover him to perform cancer surgery. Most hospital executives would not allow a physician to perform procedures that aren’t covered, according to interviews with hospital administration experts.
Mackoul, his wife and the facility administrator served as the governing board at Innovations, according to court records and Mackoul. He also said he has privileges at one Maryland hospital.
In February 2015, Jeanette Nelson, 73, a soprano gospel singer, turned to Mackoul for care after she had been diagnosed with uterine cancer.
He performed her hysterectomy without incident. Mackoul saw her again a month later to install a catheter in her chest that would better deliver chemotherapy drugs to her bloodstream. Nelson died in a hospital later that same day, her autopsy report says.
The autopsy report states that blood built up in Nelson’s chest wall and caused her lung to collapse, but the source of the blood was “not definitively identified.” However, the report concluded that her death was the result of “a complication of attempted treatment for her” cancer.
Nelson’s family alleged in a lawsuit that Mackoul punctured a vein as he installed the catheter, and his mistake caused internal bleeding that proved fatal.
George Nelson said he was devastated by the loss of his wife of 48 years, who was both devoutly religious and fascinated with murder-mystery detective shows. Before her death, the couple was looking forward to her graduation from a master’s program in cybersecurity policy.
After his wife’s passing, he said, “I didn’t care if I would have died.”
In an email, Mackoul said Jeanette Nelson’s death was related to a “major cardiac episode” and that experts he retained found no shortcomings with his care. He denied wrongdoing in the lawsuit, which reached a confidential settlement.
“Unfortunately, even under the best of circumstances and in the very best of hands, a patient can experience the most catastrophic event,” Mackoul said in an email.
Mackoul’s malpractice insurer sued him over the wrongful death case, revealing in court records that he had not been covered to perform cancer surgeries. Mackoul said in an email that the port procedure is not specifically a cancer surgery, though he was not aware of the clause at the time and was self-insured. He denied negligence in court filings, and the case reached a confidential settlement.
The question remains whether the center’s governing board was independent enough to perform the typical doctor-oversight practices, said Dr. Jonathan Burroughs, a faculty member of the American College of Healthcare Executives. And it’s a question that applies to an untold number of surgery centers.
“When push comes to shove,” he said, “the board has to make decisions in the best interest of the community and good patient care.”

Study defines spending trends among dual-eligible beneficiaries


While there has been much effort to control spending for individuals eligible for both Medicaid and Medicare in the United States, for the first time a team of Vanderbilt University health policy researchers have analyzed spending trends for this population over a multiyear period in order to gain a much clearer understanding of exactly how much is being spent and by whom.
“We measured how much Medicare spends per dual-eligible beneficiary and how much that changed between 2007 to 2015, and we compared those trends to other beneficiaries who don’t have Medicaid,” said lead author Laura Keohane, Ph.D., assistant professor of Health Policy at Vanderbilt University School of Medicine. “After adjusting for increases in Medicare payment rates, over this time period we found that dual-eligible beneficiaries over age 65 on average had very similar spending growth compared to other Medicare beneficiaries. In the most recent years of our study, dual-eligible beneficiaries had lower average annual spending growth.”
For younger Medicare beneficiaries under age 65, the team found that dual-eligible beneficiaries actually had slightly lower average spending growth over the entire time period and especially lower spending growth in the latest years of the study period.
The results of their study, which was funded by The Commonwealth Fund, were published in the August edition of Health Affairs, a peer-reviewed journal published by Project Hope.
“It is important for policy makers to know that during this period of slow growth in Medicare spending per beneficiary, spending growth for dual-eligible beneficiaries was even slower,” said one of the authors, Melinda Buntin, Ph.D., professor and chair of the Department of Health Policy at Vanderbilt, one of the study’s co-authors.
In 2016, there were 11.7 million individuals simultaneously enrolled in Medicare and Medicaid, according a recent report from the Centers for Medicare and Medicaid Services (CMS). These dual-eligible beneficiaries typically experience high rates of chronic illness, with many having multiple chronic conditions and long-term care needs. Additionally, 41 percent of dual-eligible beneficiaries have at least one mental health diagnosis. About half of dual-eligible beneficiaries rely upon some form of long-term supports and services, including institutional as well as home and community-based supports (HCBS).
Dual-eligible beneficiaries are challenged by the need to navigate two separate programs: Medicare for coverage of most health care services and prescription medications, and Medicaid for coverage of long-term care, certain behavioral health services, and for help with Medicare premiums and cost-sharing.
“It is very true that dual-eligible beneficiaries have higher spending levels than other Medicare beneficiaries, but the implication of our work is that the gap in spending levels between dual eligible beneficiaries and other beneficiaries is not increasing over time,” Keohane said. “If anything, in the last couple of years that gap has decreased a little bit.
‘So, yes, dual-eligible beneficiaries are a very high cost population, but in terms of understanding the sustainability of future spending for this population, it is at least somewhat reassuring that their spending growth rates are similar or even lower than other Medicare beneficiaries.”
Another finding of the study is that when looking at spending growth across all Medicare beneficiaries, one group with the highest average annual spending growth was individuals who use long-term nursing home use. This population had average annual spending growth rates ranging from 1.7 to 4.1 percent depending on age group and Medicaid participation.
The next step for this line of research is discovering why dual-eligible beneficiaries have lower spending growth in recent years and if that decrease is related to some of the measures that have been put in place to contain cost, such as the shift to value-based payments and efforts to better coordinate care for dual-eligible beneficiaries, Keohane said.
“To be able to benchmark dual-eligible beneficiaries’ spending growths and how  varies across different sectors and for individuals with different diseases and different demographic characteristics is helpful for being able to better identify areas where we might be able to do more for the dual-eligible population,” Keohane said. “There is better data available than ever about who is participating in Medicaid; lack of data had historically been one of the major challenges trying to research this population.
“It’s so exciting to see more and more researchers making use of that data. It can be challenging because there are a lot of variations across states in how Medicaid programs operate and important distinctions between types of Medicaid benefits, but considering the health needs of this population, we need more research attention in this area.”

Common diet elements cure lethal infections, eliminate need for antibiotics


Antibiotic use is driving an epidemic of antibiotic resistance, as more susceptible bacteria are killed but more resilient strains live on and multiply with abandon. But if antibiotics aren’t the end-all solution for infectious disease, what is?
Salk Institute researchers report that giving mice dietary iron supplements enabled them to survive a normally lethal bacterial infection and resulted in later generations of those  being less virulent. The approach, which appears in the journal Cellon August 9, 2018, demonstrates in preclinical studies that non-antibiotic-based strategies—such as nutritional interventions—can shift the relationship between the patient and  away from antagonism and toward cooperation.
“Antibiotics and antimicrobials are one of the most important advances in medicine, and we definitely need to continue efforts focused on developing new classes of antimicrobials,” says Associate Professor Janelle Ayres, who holds the Helen McLoraine Developmental Chair and is senior author of the new paper. “But we need to learn from history and think about other ways to treat infectious diseases. Our work suggests that instead of killing bacteria, if we promote the health of the host, we can tame the behavior of the bacteria so that they don’t cause disease, and we can actually drive the evolution of less dangerous strains.”
Ayres, a pioneer in researching the interactions between microbes and their hosts, is finding increasing evidence that in addition to our immune system, which kills pathogens, we have what she calls the cooperative defense system, which promotes health during host-microbe interactions. For example, in 2017 her team discovered that Salmonella bacteria can overcome a host’s natural aversion to food when sick, which results in more nutrients for the bacteria and a gentler infection for the host. And in 2015 the Ayres lab found a strain of E. coli bacteria in mice that was capable of improving the animals’ tolerance to infections of the lungs and intestines by preventing wasting—a common and potentially deadly loss of muscle tissue that occurs in serious infections.
For the current work, Ayres’ team studied a naturally occurring gastrointestinal infection in mice caused by Citrobacter rodentium (CR), which leads to diarrhea, weight loss and, in extreme cases, death. (CR is related to pathogenic E. coli that are associated with human food recalls.)
To elucidate novel mechanisms of the cooperative defense system, the Salk team used an innovative approach called lethal dose 50 (LD50), which is the dose of bacteria that kills 50 percent of the host population, while the other half of the population survives. Using what’s known as a systems biology approach, they analyzed the gene activity that was induced in the infected healthy population compared to the infected sick population, as well as the uninfected healthy mice. From this analysis, they found that host iron metabolism was increased in the infected healthy population.
To test the importance of iron metabolism in promoting the cooperative defense system during infection, Ayres and her coauthors (including undergraduate Karina Sanchez, who conducted experiments with Ayres for two years until graduating and is now a technician in the lab) gave a population of mice an LD100 dose of Citrobacter (which should kill 100 percent of the host population) and fed half the population a normal diet and the other half a diet supplemented with iron for only 14 days, after which they were returned to a normal diet.
By day 20, all of the infected mice in the no-iron group had succumbed to the infection. However, in the supplemental-iron group, 100 percent of the infected mice were alive and healthy, even at day 30. The researchers found that even if they dosed animals with 1000 times the LD100 dose of the pathogen, a two-week course of iron kept the animals alive and healthy.
Tissue analysis over the course of the experiment showed that both groups of infected mice had comparable levels of bacteria, yet the iron group appeared healthy while the no-iron group got sicker. Ayres and her team used dietary iron as a tool to investigate the mechanism by which iron metabolism cured the .
They found that the short course of dietary iron caused an acute state of insulin resistance in the mice. This reduced the amount of glucose (sugar) absorbed from the intestine, increasing the amount of sugar in the intestine for the pathogen to metabolize. Increased glucose metabolism prevented the pathogen from turning on its genes that cause disease. Additionally, the team found they could bypass iron and use glucose supplementation instead and achieve all the same results.
Interestingly, Ayres and her team found that a year later animals that were infected with Citrobacter and had received a single two-week course of dietary iron were alive and healthy, and surprisingly still colonized by the pathogen in their gastrointestinal tract. “This was so exciting to us because it suggested that we basically drove the evolution of weakened strains of the pathogen,” says Ayres.
To determine if this was the case, the team sequenced the genomes of Citrobacter that were isolated from these animals and found that in the genes necessary for causing disease, the bacteria had accumulated mutations, rendering those genes non-functional. This implied that, by increasing the amount of glucose available to the pathogen, the team was preventing the bacteria from turning on genes that cause more symptoms of sickness in its host. And, over time, by having its nutritional needs met, the pathogen was becoming less antagonistic and more cooperative.
While her team found dietary iron to be an effective treatment for infectious diarrhea in their preclinical studies, Ayres cautions that iron is not going to be the solution for all infectious diseases. “There are some infections, such as malaria, in which giving iron would be a terrible idea, as the parasite thrives on ,” says Ayres. “However, I’m really encouraged by our findings because they suggest that manipulating the metabolic state of the host and the pathogen with common dietary elements can be extremely effective in curing infections. This means we can treat infections with strategies that are more globally accessible,” says Ayres.
The group next plans to explore whether weakened bacterial strains might be used as a type of live vaccine or whether (and under what conditions) a weakened strain could revert to virulence or lethality.

Ebola virus experts discover powerful, new approach for future therapeutics


A one-two punch of powerful antibodies may be the best way to stop Ebola virus, reports an international team of scientists in the journal Cell. Their findings suggest new therapies should disable Ebola virus’s infection machinery and spark the patient’s immune system to call in reinforcements.
“This study presents results from an unprecedented international collaboration and demonstrates how 43 previously competing labs can together accelerate therapeutics and vaccine design,” says Erica Ollmann Saphire, Ph.D., professor at Scripps Research and director of the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC).
From 2013-2016, West Africa faced the deadliest Ebola outbreak the world has ever seen. By the time the outbreak was declared over, 11,325 people had died. The VIC is an international group of the world’s leading virologists, immunologists, systems biologists and structural biologists working to stop an outbreak on that scale from ever striking again.
The VIC researchers aim to understand which Ebola-fighting  are best-and why. The hope is that the most effective antibodies can be combined in a therapeutic “cocktail.” Unlike an Ebola vaccine, these cocktails could be given to those already infected, which is important for stopping a disease that tends to emerge unexpectedly in remote locations.
Ollmann Saphire and her colleagues in the VIC have published more than 40 studies in just the last five years. This landmark study is the first-ever side-by-side comparison of 171 antibodies against Ebola  and other related viruses, known as filoviruses. All antibodies in the panel were donated by different labs around the world, and many had not been previously characterized in such extensive detail.
“Through the VIC, we could test a larger pool of antibodies in parallel, which increased the potential to detect statistically significant relationships between antibody features and protection,” says Saphire. “We used this global pool of antibodies to evaluate, and streamline, the research pipeline itself.”
In addition to identifying links between antibody target locations and activity, VIC researchers tested this huge pool of antibodies to reveal which antibodies “neutralized” the virus, why neutralization assays so often disagree, and whether or not neutralization in test tubes adequately predicted how well these antibodies would protect live animals from Ebola virus infection. Unexpectedly, neutralization alone was not always associated with the protective ability of an antibody.
Notably, the scientists found nine antibodies that protected mice from infection without neutralizing the virus in test tubes. These antibodies likely fight infection by interacting with an infected person’s immune system, helping orchestrate a better immune response to the virus.
This “immune effector” activity is featured in the team’s companion study published simultaneously in Cell Host & Microbe. “The ability to evoke an immune response will likely represent a new avenue of study for therapeutic antibodies for Ebola virus infection,” says Sharon Schendel, project manager for the VIC and science writer in the Saphire lab.
From the large body of results, VIC member and Scripps Research faculty member Kristian Andersen, Ph.D., and his graduate student Karthik Gangavarapu developed a network describing how each antibody feature correlates to protection, which can serve as a guide to predict whether newly identified antibodies will have therapeutic value. Saphire says the next steps for the VIC are to further test promising antibody cocktails in non-human primates. The team will also pursue engineering of antibodies that carry signature features to better drive immune system response.
More information: Erica Ollmann Saphire et al, Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection, Cell (2018). DOI: 10.1016/j.cell.2018.07.033

Can nicotine slow memory loss?


Can nicotine slow or stop memory loss in people experiencing mild memory problems, or mild cognitive impairment (MCI)? A new study being conducted at Georgetown University Medical Center aims to find out.
Recent studies have suggested that one of the causes of memory disorders may be a reduction in a particular chemical substance in the brain. This chemical substance, known as acetylcholine, is thought to act on certain brain cells in a specific way, helping us to remember and use memories as well as affect our mood.
In people with MCI (and Alzheimer’s disease), the level of acetylcholine may be changed, and this may impair brain functioning. Preliminary studies have suggested that shorter-term administration of nicotine appears to improve memory in patients with mild memory loss and early Alzheimer’s disease (AD). It has been known for years that nicotine imitates many of the actions of acetylcholine.
To expand on this finding, a clinical trial led by Georgetown’s principal investigator, R. Scott Turner, MD, PhD, will explore whether nicotine may act to improve memory loss symptoms over the longer term and whether it may help to delay the progression of memory loss symptoms.
“We are increasingly able to detect those at risk for future Alzheimer’s disease in order to perhaps slow or stop their progression to dementia,” says Turner. “About 10-15% of those diagnosed with mild cognitive impairment (MCI) will advance to dementia each year most commonly due to Alzheimer’s disease – with a total risk of greater than 50% after 5 years. This new study is seeking volunteers with MCI to test whether treatment with a daily Nicotine skin patch can slow or stop further cognitive decline.”
This phase 2 randomized clinical trial is being conducted at approximately 30 to 40 clinical trial sites across the United States and will enroll 300 participants. Participants will wear a skin patch, containing either nicotine or placebo, for approximately 16 hours per day for two years.
Half of the participants will receive transdermal nicotine (nicotine by skin patch) called a “nicotine patch” with a dose of 7 mg per day increasing to 21 mg per day. The other half (the control group) will receive an identical patch, which does not contain an active dose of nicotine, called a “placebo patch.” The placebo patch contains a small amount of nicotine that cannot pass into the skin or be absorbed by the body.
Given that this is a randomized trial, neither the investigator nor the participant will know which group they are in.
During the first visit, participants will undergo standard physical and cognitive testing with the addition of an electrocardiogram (ECG). They will also be given a memory and thinking skills test that will be written as well as administered on an electronic device.
Some side effects could include sleepiness, diarrhea, stomach ache, muscle pain or joint pain (reported by 3-9 percent of patients using the nicotine patch) and reddening or irritation of the skin where the patch is applied (reported by 17 percent of patients using the patch).
“Since we don’t know all the possible risks and benefits as yet of Nicotine patch treatment in individuals with MCI, we advise against taking the drug for this purpose outside of the study,” says Turner.
Study participants must be between the ages of 55-90 and have a study partner who can accompany them to all appointments.

Galapagos NV downgraded to Neutral from Buy at Goldman Sachs


Galapagos NV downgraded to Neutral from Buy at Goldman Sachs. Goldman Sachs analyst Parekh downgraded Galapagos NV to Neutral from Buy, saying he sees a more balanced risk-reward profile for the stock after its 10% outperformance relative to the Dow Jones STOXX Healthcare index SXDP. The analyst also points to the company’s disappointing Cystic Fibrosis update on June 28th while looking ahead to the late-stage readouts for filgotinib’s FINCH2 trial in rheumatoid arthritis and TORTUGA trial in ankylosing spondylitis in Q3 of this year.

What’s the Hit to La Jolla Pharmaceutical


Shares of La Jolla Pharmaceutical Company (NASDAQ: LJPC), a commercial-stage biopharma focused on life-threating diseases, were down 21% as of 11:55 a.m. EDT Thursday. The huge drop is traceable to the release of second-quarter results that missed the mark.

Here’s a look at the key figures from La Jolla’s second quarter:
  • Sales of Giapreza — the company’s recently launched drug that treats a sudden drop in blood pressure — totaled $1.6 million for the period. That was well short of the $2.5 million in total sales that Wall Street was expecting.
  • Net loss was $52.3 million, or $2.02 per share. This figure was also worse than the $1.91 loss that market watchers’ had predicted.
  • Cash balance at quarter-end was $241 million.
The lower-than-hoped-for results caused traders to head for the exits.

Giapreza has only been on the market for a few months, so it’s still too early to draw any real conclusions about its chances of achieving commercial success.
La Jolla is expecting to hear from European regulators about a go/no-go decision on Giapreza in the second half of the year. If the regulatory decision is positive, the drug’s addressable market opportunity could grow by more than half, so this remains a major catalyst for investors to look forward to.
If you’re bullish on Giapreza’s potential and think that European regulators will give it the thumbs-up, then right now might not be a bad time to consider picking up a few shares.